Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Blood Cancer United (FKA The Leukemia & Lymphoma Society)

2. Address

Address1
10 G St NE
 Address2
​Suite 400
City
Washington
 State
DC
 Zip Code
20002
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Brian Connell
​2025704189
​brian.connell@bloodcancerunited.org
5. Senate ID#
​60218-12
7. Client Name Self Check if client is a state or local government or instrumentality
​Blood Cancer United (FKA The Leukemia & Lymphoma Society)
6. House ID#
​353510000
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​590,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Brian Connell
 Date
7/20/2026 4:13:55 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

HR 247 / S 46, Health Care Affordability Act;
S 2420, No Surprises Act Enforcement Act;
HR 3521, the Clinical Trial Modernization Act;
HR 5526, Biosimilar Red Tape Elimination Act;
HR 5582, S 2355, the Patients Deserve Price Tags Act;
HR 6248 / S 4027, Healthy Competition for Better Care Act
HR 6485 / S 43, Skinny Labels, Big Savings Act;
HR 6867 / S 3562, NIH Clinical Trial Integrity Act;
HR 7895, the PBM Kickback Prohibition Act;
HR 8908, the STOP GAMES Act;
HR 9393, Lower Costs, More Transparency Act;
HR 9396, the Prior Authorization Accountability Act;
HR 9397, the Premium Transparency Act;
HR 9661, Expedited Access to Biosimilars Act;
S 1041, Affordable Prescriptions for Patients Act;
S 1095, Stop STALLING Act;
S 1096, Preserve Access to Affordable Generics & Biosimilars Act
S 1097, Interagency Patent Coordination & Improvements Act;
S 2658, Medication Affordability & Patent Integrity Act;
S 3014, Ensuring Timely Access to Generics Act;
S 4509, Patients Before Monopolies Act;
Policies to address the expiration of the enhanced Advanced Premium Tax Credits;
Policies to improve transparency in hospital and insurer costs and finances;
Policies to streamline pediatric patient access to subspecialist care via telemedicine;
Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance;
Policies related to the modernization of clinical trials;
Policies related to the 2027 FDA user fee agreements;
Implementation of the No Surprises Act;
Policies related to oversight of insurance agents and brokers;
Oversight and patient impact of the 340B program;

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Brian
Connell
​
​
Kathryn
Berge
​
​
Matt
Marks
​
​
Jessica
Burnell
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

HR 3514, Improving Seniors Timely Access to Care Act;
HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage;
HR 9392, Medicare Advantage Cost Transparency Act;
S 1105, No UPCODE Act;
S 1629, Same Care, Lower Cost Act;
S 1936, Improving Access to Transfusion Care for Patients Act;
S 4886, Medicare Cost Cap Act;
CMS Interim Final Rule on Medicaid work requirements;
Regulatory and legislative proposals to expand site-neutral payment in Medicare;
Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752);
Regulatory proposals related to most-favored-nation drug pricing;


17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Brian
Connell
​
​
Kathryn
Berge
​
​
Matt
Marks
​
​
Jessica
Burnell
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research;
HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research;

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Brian
Connell
​
​
Matt
Marks
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research;
HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research;
HR 7173, Follow the Science Act;
S 4494, American Cures Act;
HR 9632, Accelerating Innovation (AI) for Kids with Cancer Act;
OMB Proposed Uniform Grants Regulation;
Policies to enable international collaboration by NIH grantees;
Policies to maintain the NIHs incremental grant funding model;

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Brian
Connell
​
​
Matt
Marks
​
​
Kathryn
Berge
​
​
Jessica
Burnell
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)